When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BCYC - Mid-stage study underway on Bicycle Therapeutics cancer candidate BT8009
Bicycle Therapeutics plc
The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating Bicycle Therapeutics' (NASDAQ:BCYC) BT8009, a Bicycle Toxin Conjugate (BTC) targeting a tumor antigen called nectin-4, in patients with advanced solid tumors.
More news on: Bicycle Therapeutics plc, Healthcare stocks news,